Greg Gibson
Regents Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Many non-coding variants influence complex traits and diseases through gene regulation, yet the mechanisms linking these variants to downstream biology remain poorly understood. Here, we present eQTLGen Phase 2 , a comprehensive genome-wide analysis of gene expression quantitative trait loci (eQTLs) in 43,301 blood samples from 52 datasets. Beyond local cis -effects, this sample size enabled the first systematic mapping of trans -eQTLs at scale. We identify cis -eQTLs for nearly all expressed genes (94.7%) and trans -eQTLs for over half (56.2%). Second, by colocalizing cis -eQTLs with trans -eQTLs, we infer a directed gene regulatory network comprising 47,554 directed gene regulatory relationships. These networks reveal how genetic perturbations in upstream regulators produce dose-dependent downstream effects, supported by Perturb-seq and ChIP-seq data. Third, integrating this network with 87 genome-wide association studies allows us to systematically prioritize trait-relevant pathways and candidate genes. Variants exerting both cis – and trans -effects are markedly more likely to colocalize with trait associations than cis -only variants, delineating a subset of functionally active cis -eQTLs from a large group with limited downstream impact. This distinction provides a conceptual framework for identifying regulatory variants that truly mediate complex trait biology. Together, these results provide a publicly available resource of cis – and trans -eQTLs and an in vivo scaffold for human gene-regulatory networks, elucidating how propagation of cis -effects modulates complex disease.
Year:
2026
Genetically transitional disease (GTD) is emerging as a new concept in genomic medicine to straddle between the traditional binary classification of monogenic and polygenic disease. Genetic testing result reports in molecular laboratories have been predicated on the monogenic disease model, which focuses on pathogenic and likely pathogenic variants. While variants of uncertain significance (VUS) are reported by laboratories, there are challenges with regard to their clinical application so that these variants are often dismissed by ordering physicians. Unlike Mendelian disorders, where genetic variants are of high penetrance and highly probabilistic, the GTD concept is employed to highlight the impact of low-to-moderate effect gene variants whose influence on disease is modified by the genetic background. The GTD concept may explain health conditions associated with variants that are necessary but not sufficient for pathogenesis, lying in the mid gray zone between Mendelian and polygenic diseases. Although VUSs may not reach the level of pathogenicity based on American College of Medical Genetics and Genomics guidelines, they could be provisionally classified as GTD-associated variants to annotate and interpret the relationship between VUS and human genetic disease. The appropriate implementation of the GTD concept could impact patient care and research by focusing attention on the individual variability of responses in various diseases.
Year:
2025
Background Single cell multi-omic investigation opens-up new opportunities to understand mechanisms of gene regulation. Existing methods for inferring transcript abundance from chromatin accessibility fail to prioritize the most relevant peaks and tend to assume positive associations between ATAC peaks and RNA counts. We hypothesize that gene regulation can be modeled as a function of combined positive and negative interactions among peaks and that causal regulatory variants are enriched in the vicinity of the most critical peaks. Results A machine learning pipeline leveraging single nuclear multiomic transcriptome and chromatin accessibility data is developed to model gene expression as a function of ATAC peak intensity. Multiome data was available for 18 immune cell types from 29 donors, 19 with Crohn’s disease. The pipeline aggregates results from three machine learning approaches (random forest regression, XGBoost, and Light GBM) as well as linear regression to identify which ATAC peaks contribute to explaining variation among donors and cell types in pseudobulk gene expression. The coefficient of determination with cross-validation was used to identify robust models which typically explain between 5% and 40% of transcript abundance, utilizing on average 47% of the ATAC peaks, representing a significant gain in predictive accuracy. The most important peaks are enriched in GWAS variants for inflammatory bowel disease and the autoimmune disease systemic lupus erythematosus, but not for rheumatoid arthritis. Conclusion Atlanta Plots visualize the proportion of ATAC peaks contributing to a predictive model of gene expression as well as the proportion of variance explained by the model. Software implementing our pipeline, “snATAC-Express”, is freely available on GitHub.
Year:
2025
Knee-Osteoarthritis (Knee-OA) is a prevalent joint disorder lacking FDA-approved cell-therapies to halt its progression. This study uses single-cell RNA sequencing to analyze bone marrow aspirate concentrate (BMAC) and stromal vascular fraction (SVF) samples in a clinical trial of autologous cell therapies. Trial site-specific variability was significant in BMAC, necessitating tailored normalization, whereas SVF was less affected, likely due to uniform subcutaneous fat sampling. Variance partitioning and tensor decomposition identified site effects in BMAC but revealed shared pathways across cell types in both tissues. Differential gene expression (DEG) analysis between responders and non-responders yielded no significant findings, though likelihood ratio testing (LRT) revealed enrichment for DEG patterns linked to disease severity, potentially masked by patient heterogeneity. Key BMAC pathways included oxidative phosphorylation, unfolded protein response, and TNFα signaling. Cell-cell communication analysis suggested enhanced HLA signaling in non-responder MSCs, consistent with inflammation, while responders showed more coordinated immune interactions. BMAC-MSCs promoted chondrocyte proliferation, whereas SVF-MSCs emphasized immune regulation. Variability in therapy outcomes reflects patient heterogeneity beyond genomic factors, complicating the immediate use of genomic profiling to guide treatment. Nonetheless, as molecular pathways are better understood, integrating genomic insights into personalized strategies may become feasible.
Year:
2025
Genome-wide association studies typically identify hundreds to thousands of loci, many of which harbor multiple independent peaks, each parsimoniously assumed to be due to the activity of a single causal variant. Fine-mapping of such variants has become a priority and since most associations are located within regulatory regions, it is also assumed that they colocalize with regulatory variants that influence the expression of nearby genes. Here we examine these assumptions by using a moderate throughput expression CROPseq protocol in which Cas9 nuclease is used to induce small insertions and deletions across the credible set of SNPs that may account for expression quantitative trait loci (eQTL) for genes associated with inflammatory bowel disease (IBD). Of the 4,384 SNPs targeted in 88 loci (an average of 50 per locus), 439 were significant and further examined for validation. From these, 98 significantly altered target gene expression in HL-60 myeloid cell line, 74 in induced macrophages from these HL-60 cells, and 78 in induced neutrophils for a total of 201 validated effects (46%), 43 of which were observed in at least two of the cell types. Considering the observed sensitivity and specificity of the controls, we estimate that there are at least 150 true positives per cell type, an average of almost 2.4 for each of the 64 eQTL for which putative causal variants have been fine-mapped. This implies that haplotype effects are likely to explain many of the associations. We also demonstrate that the same approach can be used to investigate the activity of very rare variants in regulatory regions for 89 genes, providing a rapid strategy for establishing clinical relevance of non-coding mutations.
Year:
2025
At the beginning of the COVID-19 pandemic, the Georgia Institute of Technology made the decision to keep the university doors open for on-campus attendance. To manage COVID-19 infection rates, internal resources were applied to develop and implement a mass asymptomatic surveillance program. The objective was to identify infections early for proper follow-on verification testing, contact tracing, and quarantine/isolation as needed. Program success depended on frequent and voluntary sample collection from over 40,000 students, faculty, and staff personnel. At that time, the nasopharyngeal (NP) swab, not saliva, was the main accepted sample type for COVID-19 testing. However, due to collection discomfort and the inability to be self-collected, the NP swab was not feasible for voluntary and frequent self-collection. Therefore, saliva was selected as the clinical sample type and validated. A saliva collection kit and a sample processing and analysis workflow were developed. The results of a clinical sample-type comparison study between co-collected and matched NP swabs and saliva samples showed 96.7% positive agreement and 100% negative agreement. During the Fall 2020 and Spring 2021 semesters, 319,988 samples were collected and tested. The program resulted in maintaining a low overall mean positivity rate of 0.78% and 0.54% for the Fall 2020 and Spring 2021 semesters, respectively. For this high-throughput asymptomatic COVID-19 screening application, saliva was an exceptionally good sample type.
Year:
2024
Year:
2024
By analyzing two large atlases of almost 4 million cells, we show that immune‐senescence involves a gradual loss of cellular identity, reflecting increased cellular heterogeneity, for effector, and cytotoxic immune cells. The effects are largely similar in both males and females and were robustly reproduced in two atlases, one assembled from 35 diverse studies including 678 adults, the other the OneK1K study of 982 adults. Since the mean transcriptional differences among cell‐types remain constant across age deciles, there is little evidence for the alternative mechanism of convergence of cell‐type identity. Key pathways promoting activation and stemness are down‐regulated in aged T cells, while CD8 TEM and CD4 CTLs exhibited elevated inflammatory, and cytotoxicity in older individuals. Elevated inflammatory signaling pathways, such as MAPK and TNF‐alpha signaling via NF‐kB, also occur across all aged immune cells, particularly amongst effector immune cells. This finding of lost transcriptional identity with age carries several implications, spanning from a fundamental biological understanding of aging mechanisms to clinical perspectives on the efficacy of immunomodulation in elderly people.
Year:
2024
The transferability of polygenic scores across population groups is a major concern with respect to the equitable clinical implementation of genomic medicine. Since genetic associations are identified relative to the population mean, inevitably differences in disease or trait prevalence among social strata influence the relationship between PGS and risk. Here we quantify the magnitude of PGS-by-Exposure (PGSxE) interactions for seven human diseases (coronary artery disease, type 2 diabetes, obesity thresholded to body mass index and to waist-to-hip ratio, inflammatory bowel disease, chronic kidney disease, and asthma) and pairs of 75 exposures in the White-British subset of the UK Biobank study (n=408,801). Across 24,198 PGSxE models, 746 (3.1%) were significant by two criteria, at least three-fold more than expected by chance under each criterion. Predictive accuracy is significantly improved in the high-risk exposures and by including interaction terms with effects as large as those documented for low transferability of PGS across ancestries. The predominant mechanism for PGS×E interactions is shown to be amplification of genetic effects in the presence of adverse exposures such as low polyunsaturated fatty acids, mediators of obesity, and social determinants of ill health. We introduce the notion of the proportion needed to benefit (PNB) which is the cumulative number needed to treat across the range of the PGS and show that typically this is halved in the 70 th to 80 th percentile. These findings emphasize how individuals experiencing adverse exposures stand to preferentially benefit from interventions that may reduce risk, and highlight the need for more comprehensive sampling across socioeconomic groups in the performance of genome-wide association studies.
Year:
2024
Year:
2023
Collaborators (54)
Qingbo Wang
Associate Professor
University of Tokyo
Annique Claringbould
Assistant Professor
Erasmus MC
Marie Loh
Assistant Professor
Lee Kong Chian School of Medicine
Buhle Moyo
Assistant Research Professor
Rice University
Javier Martin
Professor
Instituto de Parasitología y Biomedicina López-Neyra
Katie Burnham
University of Oxford
Sini Nagpal
Assistant Professor
Indian Institute of Technology, Bombay
Brenda WJH Penninx
Professor
-
René Pool
University of Amsterdam
Markus Scholz
Leipzig University
Farzana Jasmine
Staff Scientist
University of Chicago
Marta Eugenia Alarcón Riquelme
Scientific Director
Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica
Laura Raffield
Assistant Professor
University of North Carolina at Chapel Hill
Dirk Paul
Interim Head of PMB BioPharma
AstraZeneca UK Limited
Vasantha Kolachala
Associate Scientist
Emory University
Jouke-Jan Hottenga
Senior Researcher
Hamad Bin Khalifa University
Roel A. Ophoff
Professor
University of California, Los Angeles
Ana Viñuela
Academic, Lecturer (Teaching and Research)
University of Dundee
Pashupati Mishra
Tampere University
Emma Elisabeth Davenport
Group Leader
Wellcome Sanger Institute
José Manuel Soria Fernández
Principal Investigator. Head of Group
Hospital de la Santa Creu i Sant Pau
Julian Knight
University of Oxford
Krishnendu Roy
Dean of Engineering
Vanderbilt University
Mika Kähönen
University of Tampere
Muhammad Kibriya
Research Associate Professor
University of Chicago
Alexander Teumer
Professor
University Medicine Greifswald
Andrew Brown
Principal Investigator
University of Dundee
Toni Boltz
Massachusetts General Hospital
Zoltán Kutalik
Full Professor
University of Lausanne
Subra Kugathasan
Professor
Emory University
Katja Pahkala
Associate professor, Academy research fellow
University of Turku
Emma Raitoharju
Senior Researcher
University of Tampere
Grant Montgomery
Professorial Research Fellow
University of Queensland
Annette Peters
Chair of Epidemiology
Ludwig-Maximilians-Universität München
Kaur Alasoo
Associate Professor
University of Tartu
Joachim Thiery
Dean of Medicine and UKSH Board for Research snd Education
Kiel University
Alexis Battle
Professor
Johns Hopkins University
Holger Kirsten
Leipzig University
Olli T. Raitakari
University of Turku
Uwe Völker
Professor, Head of Department
Universitätsmedizin Greifswald
Jan Veldink
Professor of Neurology and Neurogenetics
University Medical Center Utrecht, Utrecht University
Suvi Rovio
Adjunct professor, senor researcher
University of Turku
Carlos Cruchaga
Professor
Washington University in St. Louis
Carla van der Kallen
University of Maastricht
qingping yao
Chief, Rheumatology, Professor
Stony Brook University
Robert Hogan
Professor
University of Georgia
Terho Lehtimäki
University of Tampere
Gang Bao
Rice University
Yukinori Okada
University of Tokyo
Marleen van Greevenbroek
University of Maastricht
Ciaran Lee
Lecturer
University College Cork
Yun Li
Professor
University of North Carolina
Dorret I Boomsma
Full professor
University of Amsterdam
Takanori Hasegawa
Associate Professor
Institute of Science Tokyo
Make your next move.
Prepare your application
Review drafts before you send them.